logo
That cucumber recall? You might want to check your fridge

That cucumber recall? You might want to check your fridge

Yahoo7 hours ago
Does it feel like there have been lots of cucumber recalls lately?
You are not wrong. The Food and Drug Administration has classified 137 potential salmonella recall reports for food products containing cucumbers in 2025, more than in any other year with available data. The Centers for Disease Control and Prevention has linked cucumbers to a current salmonella outbreak.
Salmonella bacteria are a major cause of foodborne illness, infecting 1.35 million people and killing 420 people each year.
Since 2012, the Food and Drug Administration has classified over 3,200 salmonella food reports, according to federal data. On average, a salmonella recall lasts nearly a year, a USA TODAY review of the FDA data found. Currently, there are 217 salmonella recall reports ongoing.
You can explore the products here:
The FDA has the authority to mandate a recall, but about 99% are voluntarily issued by the companies that make the products.
After a recall is initiated, the agency classifies the health hazard presented by the product from Class I (a reasonable probability that the product will cause serious adverse health consequences or death) to Class III (the product is not likely to cause adverse health consequences).
About 44% of food recall reports have been classified as Class I. On the other hand, 80% of salmonella food reports are classified as Class I.
Most people get infected with salmonella by eating contaminated food like raw or undercooked meat, poultry, eggs, raw or unpasteurized milk and other dairy products, and produce. According to the CDC, 1 in 25 packages of chicken in the grocery store is contaminated with salmonella.
Department of Human and Health Services Secretary Robert Kennedy Jr. is among the many promoting raw milk, but experts caution against it.
'We have people whose families have had children and parents and others sickened after drinking raw milk,' said Sandra Eskin, CEO at the nonprofit Stop Foodborne Illness. 'It has salmonella in it, it can have E. coli, and it can have any number of pathogens. That's why they invented pasteurization.'
Warmer weather can also create ideal conditions for the bacteria to grow, so it's recommended to refrigerate perishable foods.
Other sources of salmonella include contaminated water and the handling of animals.
Symptoms start within six hours to six days from the time of exposure and include fever, diarrhea, nausea, vomiting and stomach pain. Most people recover within 4 to 7 days without treatment, but some cases lead to hospitalization and death.
Since the start of President Donald Trump's second term, there have been severe cuts and the federal health services workforce is expected to drop from 82,000 to 62,000, USA TODAY previously reported.
Trump argued the cuts are a way to save taxpayers' money, but experts say allocating resources towards food safety is critical.
An FDA spokesperson told USA TODAY in an email statement that the agency prioritizes food safety and is committed to working with all stakeholders.
'The layoffs relate to administrative staff positions in the FDA. There has been no impact to operational investigators conducting food safety inspections,' the FDA spokesperson said.
Over a decade ago, when annual salmonella numbers were estimated to be lower, the U.S. Department of Agriculture estimated that foodborne illness cost the country $3.7 billion per year, most of which was attributed to premature deaths.
Eskin, who previously worked at the U.S. Department of Agriculture overseeing food safety and inspections, said recalls are essential for public health.
'A recall is the last line of defense that you and I have to prevent getting sick,' Eskin said, 'if we're going to a restaurant, or more importantly, going to the grocery store.'
Dr. Susan Kansagra, chief medical officer at the Association of State and Territorial Health Officials, said in an email statement that federal funds support a wide range of state-level activities related to foodborne illness, like laboratory testing, case reporting, and guiding providers and the public on prevention and treatment.
'Loss of funding and staffing decreases our national capacity to do these activities and therefore quickly detect and respond to foodborne illness,' Kansagra said.
This article originally appeared on USA TODAY: After flood of cucumber recalls, you should check your fridge
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations

Yahoo

time31 minutes ago

  • Yahoo

MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention ('CDC') adopted new recommendations for the use of RSV vaccines in the upcoming respiratory virus season. The revised recommendations lower the recommended age for RSV vaccination. Now, adults aged 50-59 who are at higher risk of severe illness from the disease are advised to receive a single dose of the vaccine. The previous CDC guidance recommended RSV vaccines for people aged 75 and older, as well as those aged between 60-74 who were at high risk of the disease. Per the CDC's website, this recommendation was officially adopted last week by the current HHS secretary, Robert F. Kennedy, Jr. Although the CDC director typically accepts or rejects such recommendations, the position is currently vacant, so Kennedy fulfilled that role. President Trump has backed Susan Monarez as his nominee for the post, but her appointment is still pending confirmation by the U.S. Senate. The broader recommendations come as a surprise because the members of the CDC's advisory committee — who initially made the recommendation earlier this year — were all removed by RFK Jr. last month. Year to date, the stock has lost 27% compared with the industry's 2% decline. Image Source: Zacks Investment Research The expanded CDC recommendations widen Moderna's addressable market for its RSV vaccine, mResvia. By lowering the recommended age group, the guidance opens up a new segment of eligible patients who were previously excluded. Moderna is one of a handful of companies marketing an RSV vaccine. Though mResvia was initially approved last year for use in people aged 60 and older, the FDA expanded its label last month to include high-risk individuals aged between 18-59. Despite commercially launching the vaccine last year, mResvia sales were modest as it was approved and recommended later in the contracting season. By that point, many people had already completed their vaccinations with either GSK's GSK Arexvy or Pfizer's PFE Abrysvo. RSV vaccines gained traction in 2023 with the initial approvals of Arexvy and Abrysvo — the first FDA-approved RSV vaccines. At the time, the CDC issued blanket approvals for use among individuals aged 60 and older. However, the CDC later narrowed that guidance, which trimmed the target market last year. That, combined with the earlier availability of GSK and Pfizer's offerings, gave both companies a dominant position over Moderna. Both GSK and Pfizer vaccines are already approved for use in individuals aged 60 and older. While GSK's Arexvy is approved for use in high-risk individuals aged 50-59, PFE's Abrysvo is approved for use in high-risk people aged 18-59. The Pfizer vaccine is also approved for use in infants through maternal immunization. Moderna, Inc. price | Moderna, Inc. Quote Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Melania Trump meets with patients, visits garden at Washington children's hospital
Melania Trump meets with patients, visits garden at Washington children's hospital

Washington Post

time33 minutes ago

  • Washington Post

Melania Trump meets with patients, visits garden at Washington children's hospital

WASHINGTON — First lady Melania Trump was set to visit with sick patients at Children's National hospital in Washington on Thursday as the children made Fourth of July arts and crafts ahead of the holiday. Trump, continuing a tradition of support by first ladies for the pediatric care center, was also expected during her visit to visit a rooftop 'healing' garden she dedicated during the first Trump administration to first ladies of the United States.

Sunvozertinib Wins Approval for EGFR-Mutated NSCLC
Sunvozertinib Wins Approval for EGFR-Mutated NSCLC

Medscape

timean hour ago

  • Medscape

Sunvozertinib Wins Approval for EGFR-Mutated NSCLC

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion mutations that's progressed on or after platinum-based chemotherapy. The agency also approved Oncomine Dx Express Test (Life Technologies Corporation) as a companion diagnostic to detect the mutations. The oral EGFR inhibitor is the first small molecule approved in the US for the indication; it was previously approved in China. The intravenous bispecific antibody amivantamab-vmjw (Rybrevant, Johnson & Johnson) also carries a second-line indication for EGFR exon 20 insertion mutated advanced/metastatic NSCLC, as well as a first-line indication with carboplatin and pemetrexed. Dizal is going for a first-line indication, too. The company recently announced completion of enrolment in a phase 3 trial pitting sunvozertinib against platinum-based chemotherapy for the upfront treatment of EGFR exon 20 insertion mutated NSCLC. The new second-line approval was based on WU-KONG1B, a multinational dose finding trial. All subjects had previous platinum-based chemotherapy and 43.4% had also received immunotherapy; 13.3% had been on amivantamab. Among 85 patients on 200 mg sunvozertinib daily, the overall response rate was 46% and the duration of response was 11.1 months. Labelling warns of the possibility of interstitial lung disease/pneumonitis, gastrointestinal adverse reactions, dermatologic issues, ocular toxicity, and embryo-fetal toxicity. Diarrhea, skin rash, and creatine phosphokinase increase were the most common drug-related treatment emergent adverse events in the trial, with most events being grade 1 or 2. The recommended dose is 200 mg orally once daily with food until disease progression or unacceptable toxicity. M. Alexander Otto is a physician assistant with a master's degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape. Alex is also an MIT Knight Science Journalism fellow. Email: aotto@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store